The method of claim 85 wherein the composition is daptomycin that is essentially free of each of impurities 1 to 14 defined by peaks 1-14 shown in <figref idref="DRAWINGS">FIG. 12</figref>.

The composition of claim 97, wherein the size selection technique is ultrafiltration or size exclusion chromatography.

The composition of claim 183, wherein the daptomycin composition is at least or about 97% pure.

The method according to claim 48 wherein the dose is 4 mg/kg.

The method according to claim 48 wherein the dose is 6 mg/kg.

The method according to claim 14, wherein the dose is 4 mg/kg administered once every 24 hours.

The method according to claim 14, wherein the dose is 6 mg/kg administered once every 24 hours.

The method according to claim 33, wherein the dose is 4 mg/kg.

The method according to claim 33, wherein the dose is 6 mg/kg.

The pharmaceutical composition of claim 22, wherein the daptomycin is obtained from the daptomycin aggregate by a method comprising the steps of a) filtering the daptomycin aggregate under conditions in which the daptomycin aggregate is retained on the filter; and b) collecting the daptomycin aggregate. view more

The composition of claim 52, wherein a) the composition is a lyophilized powder compatible with a pharmaceutically acceptable carrier for the treatment of an infection by a daily intravenous dose of 1 to 12 mg/kg of the daptomycin in a reconstituted solution of the lyophilized powder in the pharmaceutically acceptable carrier; and b) the daptomycin has a purity of about 94 to 96% relative to impurities 1-14 defined by peaks 1-14 shown in FIG. 12, the daptomycin having less than 1% of the lactone hydrolysis product of daptomycin, less than 4% anhydro daptomycin and less than 4% of the β-isomer of daptomycin. view more